Joint Formulary & PAD

Infliximab - Inflammatory bowel disease

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

PAD Profile

ChemicalSubstance :
Infliximab
Indication :
Inflammatory bowel disease
Group Name :
Keywords :
IBD, biologic, NICE, biosimilar Sequential use of biologic medicines, TNF alpha inhibitor, Cytokine modulator, Crohns disease, Inflammatory Bowel Disease, subcutaneous, pre-filled pen, pre-filled syringe
Brand Names Include :
Remicade, Inflectra, Remsima, Flixabi, Zessly
Important Information :
For UC & CD. Prescribe by brand
Latest Additions Date From :
Latest Additions Date To :
Supporting Documents :
6

Committee Recommendations (2)

The Surrey Heartlands Integrated Care System Area Prescribing Committee has agreed the reviewed and updated IBD immunomodulator pathway, which is to be found on the IBD guidelines page.

The Medicines and Healthcare Products Regulatory Agency (MHRA) recommends to prescribe biological products by brand name to ensure that substitution of a biosimilar product does not occur when the medicine is dispensed by the pharmacist. Https://www/gov/uk/drug-safety-update/biosimilar-products

Primary care prescriber should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.